Cumberland Pharmaceuticals (NASDAQ: CPIX), a specialty pharmaceutical company, announced yesterday that it has named Adam Haeberle, PhD as its new senior director, clinical and regulatory affairs.

In the new role, Haeberle will be responsible for overseeing the company's product development team in support of its efforts to design and implement clinical studies.

Dr Haeberle joins the company from Amgen Inc, where he held a series of director-level clinical development roles, including development clinical director. At Amgen, he led clinical development initiatives and was responsible for innovating and increasing the overall efficiency of Amgen's cardiovascular portfolio. Before Amgen, Haeberle was senior manager, clinical development at Baxter Healthcare Corporation, where he led post-approval clinical activities for Baxter's Alpha-1 Protease Inhibitor franchise, encompassing the brands Aralast and Glassia, used in the treatment of lung disease. He also held several significant positions, including associate director, clinical operations and regulatory affairs, in biotech start-ups and government. He has managed clinical development, regulatory activities and the overall program for an NIH government contract. He served as a captain in the United States Army's Medical Service Corps, where he managed the development of IV Artesunate for the treatment of severe and complicated malaria.

AJ Kazimi, Cumberland CEO, said, 'It's a pleasure to welcome Adam to our product development team. Adam is uniquely qualified to help deliver on our exciting pipeline, and brings extensive experience in clinical development, which will be key to our company's continued success.'